DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Goldman Sachs - 1 Goldman - 1 Morgan Stanley - 1 it's - 1 Piper Sandler - 1 Piper - 1 Apple - 1 Q - 1
Top related locs:
Singapore Asia Brazil InVitae Invitae Acadia ImmunoGen
Top related orgs:
Kymera Therapeutics - 2 Nvidia - 1 NVIDIA - 1 RBC - 1 Apple - 1 Microsoft - 1 Meta - 1 Bank of America - 1

Search resuls for: "Kymera Therapeutics"


3 mentions found


☆ Here are Monday's biggest analyst calls: Apple, Nvidia, Tesla, Meta, Amazon, Microsoft, Spotify, Ferrari & more
  + stars: | 2024-04-22 | by ( Michael Bloom | ) www.cnbc.com   time to read: +7 min
Morgan Stanley reiterates Apple as overweight Morgan Stanley lowered its price target on the stock to $210 per share from $220 but says it's sticking with Apple. Bank of America reiterates Amazon as buy Bank of America said it's bullish heading into Amazon earnings next week. Bank of America reiterates Tesla as neutral Bank of America said it's sticking with its neutral rating on Tesla shares. Morgan Stanley upgrades Alcoa to equal weight from underweight Morgan Stanley said it sees a more balanced risk/reward for shares of Alcoa. Bank of America reiterates Apple as buy Bank of America says Apple is a top pick at the firm.
Persons: Goldman Sachs, Goldman, Morgan Stanley, it's, Piper Sandler, Piper, Apple, Q, Q revs, Papa, Stifel, Papa John's, Jefferies, Mizuho, JPMorgan, Raymond James downgrades, Raymond James, TD Cowen, BRBR, BMO downgrades, Tesla, Oppenheimer Organizations: Nvidia, NVIDIA, RBC, Apple, Microsoft, Meta, Bank of America, JPMorgan, Cisco, Deutsche Bank, Realty Trust, Deutsche, Brands, BMO, of America, Alcoa, Kymera Therapeutics, " Bank of America Locations: Singapore, Asia, Brazil
☆ A biotech hedge fund that counts Yale’s endowment among its clients bought a new stake in this genetic testing company
  + stars: | 2023-08-16 | by ( Sarah Min | ) www.cnbc.com   time to read: +1 min
Founded by brothers Julian and Felix Baker in 2000, the health care hedge fund focuses on biotech and life sciences investing. The biotech stock with a focus on neuroscience has surged more than 84% this year. Baker Bros. doubled down on its bet in Kymera Therapeutics , which it raised by more than 51%. The hedge fund also took new stakes in ImmunoGen , which has more than tripled this year, soaring 216%, and Day One Biopharmaceuticals , which is down by 34%. The hedge fund lowered its exposure to the biotech company, which develops treatments for cancer, by 5%.
Persons: Baker, Tisch, Julian, Felix Baker, Seagen, Yun Li Organizations: Baker Bros, Advisors, Yale, Acadia Pharmaceuticals, Kymera Therapeutics Locations: InVitae, Invitae, Acadia, ImmunoGen
☆ These are the top 10 stock plays for 2023, according to UBS
  + stars: | 2022-12-14 | by ( Carmen Reinicke | ) www.cnbc.com   time to read: +5 min
As the year winds down, investors are looking forward to 2023 and wondering where they should place their top bets. Analysts that cover companies are mulling the same question, prompting UBS to put together a list of its top conviction picks for 2023. The stock which is poised for the largest gain is Kymera Therapeutics , a biotechnology firm that UBS thinks could surge 240% to its target price. She added that UBS expects updates across all four programs in the near term as well as over 2023. Analysts that cover companies are mulling the same question, prompting UBS to put together a list of its top conviction picks for 2023.
0 next >>
Total: 3